ArticleCancer research2012
Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer.
Article in Cancer research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- CDK5: an oncogene or an anti-oncogene: location location location.Molecular cancer · 2023Review
- Activation Mechanism of RhoA Caused by Constitutively Activating Mutations G14V and Q63L.International journal of molecular sciences · 2022Article
- Frequent Downregulation and Promoter Hypermethylation of DLC1: Relationship with Clinical Outcome in Gallbladder Cancer.Journal of gastrointestinal cancer · 2022Article
- Cancer-Associated Point Mutations in theCancer research · 2020Article
- Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.Cancer biomarkers : section A of Disease markers · 2020Article
- HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia.Journal of translational medicine · 2019Article
- E-cadherin clone 36 nuclear staining dictates adverse disease outcome in lobular breast cancer patients.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Upregulation of DLC-1 inhibits pancreatic cancer progression: Studies with clinical samples and a pancreatic cancer model.Oncology letters · 2019Article
- The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma.Laboratory investigation; a journal of technical methods and pathology · 2018Article
- Lentivirus-mediated knockdown of P27RF-Rho inhibits hepatocellular carcinoma cell growth.Contemporary oncology (Poznan, Poland) · 2017Article
- DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers.Oncotarget · 2016Article
- The Role of Chromosomal Instability and Epigenetics in Colorectal Cancers Lacking β-Catenin/TCF Regulated Transcription.Gastroenterology research and practice · 2016Article
- Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.Molecular medicine reports · 2015Article
- MicroRNA-106b promotes colorectal cancer cell migration and invasion by directly targeting DLC1.Journal of experimental & clinical cancer research : CR · 2015Article
- Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16.Molecular cancer · 2015Article
- CDK5 is a major regulator of the tumor suppressor DLC1.The Journal of cell biology · 2014Article
- Cooperation of DLC1 and CDK6 affects breast cancer clinical outcome.G3 (Bethesda, Md.) · 2014Article
- Deleted in liver cancer-1 (DLC1): an emerging metastasis suppressor gene.Molecular diagnosis & therapy · 2014Review
- Isolation of Mouse Embryo Fibroblasts.Bio-protocol · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
The tumor suppressor gene deleted in liver cancer-1 (DLC1), which encodes a protein with strong RhoGAP (GTPase activating protein) activity and weak Cdc42GAP activity, is inactivated in various human malignancies. Following Dlc1 inactivation, mouse embryo fibroblasts (MEF) with a conditional Dlc1 knockout allele reproducibly underwent neoplastic transformation. In addition to inactivation of Dlc1 and increased activity of Rho and Cdc42, transformation depended on the subsequent decreased expression of the Cdk4/6 inhibitors p15(Ink4b) and p16(Ink4a) together with increased expression and activation of Cdk4/6. The level of expression of these cell-cycle regulatory genes was relevant to human tumors with low DLC1 expression. Analysis of publicly available annotated datasets of lung and colon cancer with gene expression microarray profiles indicated that, in pairwise comparisons, low DLC1 expression occurred frequently together (P < 0.01) with downregulation of p15(Ink4b) or p16(Ink4a) or upregulation of CDK4 or CDK6. In addition, an unfavorable prognosis (P < 0.05) was associated with low DLC1 and low p15(Ink4b) in lung cancer and colon cancer, low DLC1 and low p16(Ink4a) in lung cancer, low DLC1 and high CDK4 in lung cancer, and low DLC1 and high CDK6 in colon cancer. Thus, several genes and biochemical activities collaborate with the inactivation of DLC1 to give rise to cell transformation in MEFs, and the identified genes are relevant to human tumors with low DLC1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.